11. ADDITIONAL INCLUSION CRITERIA FOR BRAF MUTATION (COHORT 1): Patients with a BRAFV600E mutation being considered for the triplet combination (vemurafenib + cobimetinib + atezolizumab) must meet the following end organ function criteria: ANC >/= 1.5 × 10^9/L without granulocyte colony-stimulating factor support, WBC count >/= 2.5 × 10^9/L, Lymphocyte count >/= 0.5 × 10^9/L, Platelet count >/= 100 × 10^9/L without transfusion, Hemoglobin >/= 9.0 g/L without transfusion.